Ahold Delhaize: Walmart 1Q24/25 results. Azelis: Share placement by EQT and PSP. Belgian telcos: Digi mobile prices to be well below competition, targets 10% mkt share. EVS: Slow start, sales guidance held on strong pipeline, EBIT guidance below consensus. Exmar: Stable start to the year. Prosus: Fabricio Bloisi (CEO iFood) appointed as group CEO. Sif Group: 1Q24 pretty much in line, timing shifts a bit
AEGON: 1Q24, new unexpected SBB, underlying OCG better, strong ratios across. Belgian telecoms: Digi to start with mobile. CFE: Preview - forecasting revenue numbers… D'Ieteren: Belron US peer Boyd 1Q24 below consensus, warns on 2Q24 growth. Econocom: Joins consortium formed by Onepoint and Butler Industries to acquire Atos. KBC: 1Q24 better across, special dividend, capital distribution pushed back to 1H25. Syensqo: 1Q24 a touch better, positive earnings momentum confirmed. Umicore:...
Aalberts: Preview - steady in difficult markets. ABN AMRO: 1Q24 overshadowed by weaker capital, even if a strong set. AEGON: 1Q24 Preview (trading update). Alfen: Preview - clarity on one-off Pacto costs crucial. B&S Group: Bolt-on acquisition in Personal Care. Belgian telcos: BIPT notes that fibre cooperation negotiations not ready by 15 May. EVS: 1Q24 preview. Euronext: Another record, with Beats by Boujnah. Montea: €12m acquisition in the Port of Ghent. Staffing: Dutch Perio...
MaaT completed a global offering (reserved offering and primary bid offering) of approx. 2.3m new ordinary shares at a price of € 8 per share (discount of approx. 14% vs. last close) for gross proceeds of € 19.2m (net proceeds € 17.3m). The funds lift the financing overhang for MaaT and extend the company's runway to early 1Q25 (previously end 3Q24). This provides funding beyond the topline readout (ORR) from the phase 3 (ARES) trial of MaaT013 in aGvHD expected in mid 4Q24, which we view as the...
LYON, France--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE ET LES INFORMATIONS QU’IL CONTIENT SONT RESTREINTS ET NE SONT PAS DESTINES A LA DIFFUSION, A LA PUBLICATION OU A LA DISTRIBUTION, EN TOUT OU PARTIE, DIRECTEMENT OU INDIRECTEMENT, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU AUX ETATS-UNIS OU DANS TOUT AUTRE JURIDICTION DANS LAQUELLE UNE TELLE DIFFUSION, PUBLICATION OU DISTRIBUTION SERAIT ILLEGALE. CE COMMUNIQUE EST ETABLI A TITRE D’INFORMATION UNIQUEMENT ET NE CONSTITUE PAS, NI NE CONTIENT AUCUNE INVITATION, SOLLICITATION, RECOMMANDATION, OFFRE OU CONSEIL A QUICONQUE...
LYON, France--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE ET LES INFORMATIONS QU’IL CONTIENT SONT RESTREINTS ET NE SONT PAS DESTINES A LA DIFFUSION, A LA PUBLICATION OU A LA DISTRIBUTION, EN TOUT OU PARTIE, DIRECTEMENT OU INDIRECTEMENT, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU AUX ETATS-UNIS OU DANS TOUT AUTRE JURIDICTION DANS LAQUELLE UNE TELLE DIFFUSION, PUBLICATION OU DISTRIBUTION SERAIT ILLEGALE. CE COMMUNIQUE EST ETABLI A TITRE D’INFORMATION UNIQUEMENT ET NE CONSTITUE PAS, NI NE CONTIENT AUCUNE INVITATION, SOLLICITATION, RECOMMANDATION, OFFRE OU CONSEIL A QUICONQUE...
Two Directors at UCB SA sold/bought 4,187 shares at 129.920USD. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
US telco services provider Syniverse is put up for sale and Proximus is rumoured to be looking at the file carrying a price tag of EUR 1.4-1.9bnAlthough we do see the potential synergies given Proximus' presence in such services with Telesign, BICS and Route Mobile, it seems too far fetchedIn the coming weeks, we expect positive newsflow from collaboration on fiber in Belgium and a mini-CMD on Route MobileAll in all, we stick to our BUY rating and DCF-derived TP of EUR 11.0 per share. Proxi...
• Following regulatory clearing, Proximus announced the closing of the Route Mobile transaction• Post-reinvestment of Route Mobile shareholders, the net cash out for Proximus would be EUR 634m. A webcast will be organized on June 3• We stick to our BUY rating and EUR 11.0 TP, DCF-based
MaaT Pharma provides a broad overview of its recent activities and expected milestones. We can expect a number of updates from MaaT's pipeline in the coming months, the most notable of which is the primary endpoint readout (28 day GI-ORR) from the Ph3 ARES trial of enema MaaT013 in aGvHD, which is expected mid 4Q24. We reiterate our € 15 TP and Buy rating.
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, fait le point sur ses activités et rappelle les principales étapes attendues pour l’année 2024. Hervé Affagard, directeur général et co-fondateur de MaaT Pharma, a déclaré : « nous avançons avec confiance vers les résultats de la Phase 3 pour MaaT013, tout en continuant à atteindre des jalons clés et à créer de la valeur...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024. Hervé Affagard, CEO and co-founder of MaaT Pharma said: “We're confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders. Recent data at the EBMT annual congress underscores MaaT013's potential in aGvHD whe...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem Therapies™ (MET)1 visant à améliorer la survie des patients atteints de cancers, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 30 avril 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date Nombre total d’actions composant le capital...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.